I am fairly confident that they are not part of the current urgently awaited chip.
I can also say to you as a matter of legal certainty that as this paper has now been published and the intellectual property has been fully disclosed to all the world it can no longer be patented by anyone including the authors/discoverers of these astrocytes.
If you publish or disclose before you lodge your patent you are a dead duck.
My personal view is the same as Madx in that these astrocytes are not competitors to AKIDA in the same way as the spinal cord is not a competitor to the brain.
On the issue of the secret sauce we know BRN rushed to lodge an Omnibus patent to cover everything they could possibly patent so given the quality of the patent work we have seen to date I see no reason to thing the secret sauce if it exists is the subject of a patent application.
My reading suggests that if it is around the chemical composition of the membrane there would be an enormous amount of prior art to be considered and distinguished before it is granted.
- Forums
- ASX - By Stock
- BRN
- 2020 BRN Discussion
2020 BRN Discussion, page-3814
-
-
- There are more pages in this discussion • 25,500 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BRN (ASX) to my watchlist
|
|||||
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $361.9M |
Open | High | Low | Value | Volume |
19.5¢ | 20.0¢ | 19.5¢ | $134.2K | 684.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
81 | 1754633 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 619006 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
80 | 1734940 | 0.195 |
63 | 1720741 | 0.190 |
30 | 1704532 | 0.185 |
51 | 1549834 | 0.180 |
18 | 613862 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 569508 | 21 |
0.205 | 837585 | 20 |
0.210 | 1378483 | 25 |
0.215 | 533493 | 23 |
0.220 | 678461 | 24 |
Last trade - 10.30am 16/07/2024 (20 minute delay) ? |
Featured News
BRN (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online